Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C.
Lynce F, et al. Among authors: jochems c.
medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559.
medRxiv. 2023.
PMID: 38105958
Free PMC article.
Updated.
Preprint.